Please login to the form below

Not currently logged in
Email:
Password:

Gary Nabel to lead Sanofi's strategy council

Pharma firm’s chief scientific officer replaces Richard Klausner

Gary Nabel, SanofiSanofi has appointed its chief scientific officer Dr Gary Nabel as chair of its strategic development and scientific advisory council (SDSAC).

He succeeds Dr Richard Klausner, a former executive director for Global Health of the Bill and Melinda Gates Foundation, who led the council since March 2011.

The SDSAC was created in November 2010 to advise Sanofi on emerging areas of science and technology to support its R&D activities and also aims to enhance the pharma company's collaborative efforts through the development of a strong network of scientists and institutional partnerships.

Commenting on Dr Nabel's appointment, Sanofi's president global R&D Dr Elisa Zerhouni said: “I am delighted that Dr Gary Nabel will continue to make this council a vital part of our efforts to open Sanofi's research and development to outside perspectives.

“I also wish to recognise and warmly thank Dr Richard Klausner who has been an outstanding adviser to the council. Under his leadership and invaluable experience, he has played a key role in setting out the role and composition of a group of experienced and internationally recognised advisers.”

Dr Nabel joined Sanofi as chief scientific officer in November last year, having previously served as director of the vaccine research centre (VRC) of the National Institute of Allergy and Infectious Diseases – part of the US National Institutes of Health.

His predecessor as SDSAC chair Dr Klausner, in addition to his work at the Bill and Melinda Gates Foundation, also served as director of the National Cancer Institute for the six years to 2001 and is currently a partner at San Francisco-based venture firm and the Column Group.

10th January 2013

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics